SCHEMBL5280376

SCHEMBL5280376

O=S(=O)(Nc1ccc(F)cc1F)c1ccc(Nc2ccc(F)cc2F)c2nonc12

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.55
KMT2A Q03164 3/20 0.55
ACLY P53396 3/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
THRB P10828 1/20 0.43
TP53 P04637 1/20 0.42
CCR2 P41597 2/20 0.41
SOS1 Q07889 1/20 0.40
AXL P30530 1/20 0.39
PTGES2 Q9H7Z7 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PIK3CD O00329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5282149 0.86 BRD4 (0.52) POLBKMT2ATSHRHSD17B10MEN1
SCHEMBL5287473 0.86 ACLY (0.54) POLBKMT2AACLYLMNATSHR
SCHEMBL5295964 0.86 POLB (0.50) POLBKMT2AACLYLMNATSHR
SCHEMBL5278920 0.79 POLB (0.57) POLBKMT2AACLYCCR2PIK3C3
SCHEMBL5285855 0.78 POLB (0.54) POLBKMT2AACLYTSHRMEN1
SCHEMBL5277982 0.78 EPAS1 (0.51) POLBKMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL5280702 0.76 KMT2A (0.46) POLBKMT2AHSD17B10SOS1MEN1
SCHEMBL5297107 0.74 MCL1 (0.52) POLBKMT2AACLYLMNATP53
SCHEMBL7877642 0.72 MCL1 (0.58) POLBKMT2AACLYLMNATSHR
SCHEMBL5301539 0.72 POLB (0.52) POLBKMT2AACLYLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP POLB 2997/4885KMT2A 1303/4885ACLY 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.